UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C.  20549

                                 Form 10-K-A

                Annual Report Pursuant to Section 13 or 15(d)
                   of the Securities Exchange Act of 1934

                For the fiscal year ended December 31, 1995
                       Commission File Number 0-11997

                        Carrington Laboratories, Inc.
             (Exact name of Registrant as specified in its charter)      

        Texas                                             75-1435663
(State of Incorporation)                             (IRS Employer ID No.)

                    2001 Walnut Hill Lane, Irving, Texas 75038
                     (Address of principal executive offices)

       Registrant's telephone number, including area code:  (214) 518-1300

           Securities registered pursuant to Section 12(b) of the Act:

       Title of each class                Name of exchange on which registered
       -------------------                ------------------------------------
             None

            Securities registered pursuant to Section 12(g) of the Act:

                         Common Stock ($.01 par value)
                               (Title of class)
                        Preferred Share Purchase Rights
                               (Title of class)

Indicate by check mark whether the Registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 
1934 during the preceding 12 months (or for such shorter period that the 
Registrant was required to file such reports), and (2) has been subject to such 
filing requirements for the past 90 days.  Yes X      No   

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 
of Regulation S-K is not contained herein, and will not be contained, to the 
best of the Registrant's knowledge, in definitive proxy or information 
statements incorporated by reference in Part III of this Form 10-K or any 
amendment to this Form 10-K.  [ ]

   
The aggregate market value of the voting stock held by non-affiliates of the 
Registrant on March 15, 1996, was $231,721,284.  (This figure was computed on 
the basis of the closing price of such stock on the NASDAQ National Market on 
March 15, 1996 using the aggregate number of shares held on that date by, or 
in nominee name for, shareholders who are not officers, directors or record 
holders of 10% or more of the Registrant's outstanding voting stock.  The 
characterization of such officers, directors and 10% shareholders as affiliates 
is for purposes of this computation only and should not be construed as an
admission for any other purpose that any of such persons are, in fact, 
affiliates of the Registrant.)

Indicate the number of shares outstanding of each of the Registrant's classes 
of Common Stock, as of the latest practicable date:
8,657,421 shares of Common Stock, par value $.01 per share, were outstanding 
on March 15, 1996.
    
                       DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant's proxy statement for its annual meeting of 
shareholders to be held on May 23, 1996 are incorporated by reference into 
Part III hereof, to the extent indicated herein.

                                STATEMENT

This amendment is filed soley for the purpose of Amending that portion of the 
facing page that describes the securities registered persuant to Sections
12(b) and 12(g) of the Act.

                               SIGNITURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this Report to be signed on its 
behalf by the undersigned, thereunto duly authorized.


                                                 CARRINGTON LABORATORIES, INC.


Date:  October 4, 1996                           By: /s/ Sheri L. Pantermuehl
                                                   --------------------------  
                                                    Sheri L. Pantermuehl, CFO